deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT03335540

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

ADaptiVe Biomarker Trial That InformS Evolution of Therapy

Sponsor: Bristol-Myers Squibb

Conditions Advanced Cancer
Interventions Cabiralizumab IDO1 Inhibitor Ipilimumab Nivolumab Radiation Therapy Relatlimab
Updated 19 times since 2017 Last updated: Sep 23, 2022 Started: May 7, 2018 Primary completion: Mar 31, 2021 Completion: Aug 25, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03335540, this PHASE1 trial focuses on Advanced Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 19 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE1

▶ Show 14 earlier versions

  1. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  2. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  3. Nov 2019 — Jun 2020 [monthly]

    Recruiting PHASE1

  4. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  5. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  6. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  7. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  8. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1

  9. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  10. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  11. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  13. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  14. Dec 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations